Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

CNBX Pharmaceuticals (CNBX) Cost of Revenue (2016 - 2024)

CNBX Pharmaceuticals (CNBX) has disclosed Cost of Revenue for 9 consecutive years, with $6220.0 as the latest value for Q1 2024.

  • For the quarter ending Q1 2024, Cost of Revenue changed N/A year-over-year to $6220.0, compared with a TTM value of $10040.0 through Feb 2025, down 42.93%, and an annual FY2025 reading of $40445.0, down 24.5% over the prior year.
  • Cost of Revenue was $6220.0 for Q1 2024 at CNBX Pharmaceuticals, up from $3820.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $7551.0 in Q4 2020 and bottomed at $3820.0 in Q4 2021.
  • Average Cost of Revenue over 3 years is $5863.7, with a median of $6220.0 recorded in 2024.
  • The sharpest move saw Cost of Revenue crashed 68.69% in 2020, then tumbled 49.41% in 2021.
  • Year by year, Cost of Revenue stood at $7551.0 in 2020, then crashed by 49.41% to $3820.0 in 2021, then soared by 62.83% to $6220.0 in 2024.
  • Business Quant data shows Cost of Revenue for CNBX at $6220.0 in Q1 2024, $3820.0 in Q4 2021, and $7551.0 in Q4 2020.